Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.350
-0.160 (-10.60%)
May 15, 2026, 4:00 PM EDT - Market closed
Allarity Therapeutics Employees
As of December 31, 2025, Allarity Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$43,125
Profits / Employee
-$1,406,125
Market Cap
20.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2024 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2023 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2022 | 9 | -4 | -30.77% | 9 | 0 |
| Dec 31, 2021 | 13 | -1 | -7.14% | 13 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Longeveron | 38 |
| Quince Therapeutics | 38 |
| Curis | 24 |
| Citius Pharmaceuticals | 23 |
| OSR Holdings | 22 |
| Lipocine | 14 |
| VYNE Therapeutics | 10 |
ALLR News
- 2 days ago - Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers - GlobeNewsWire
- 9 days ago - Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - GlobeNewsWire
- 12 days ago - Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - GlobeNewsWire
- 20 days ago - Allarity receives notice of allowance from USPTO - TheFly
- 20 days ago - Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office - GlobeNewsWire
- 6 weeks ago - Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - GlobeNewsWire
- 2 months ago - Allarity closes $20M financing for stenoparib advancement - TheFly
- 2 months ago - Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization - GlobeNewsWire